Facebook
Twitter
LinkedIn
Forward
Obesity Medicine 2023 - Spring Obesity Summit
|
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place.
|
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
|
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity.
|
What anti-obesity medications are in development?
|
Rather than weight/BMI, body composition is a better way for individualized assessment of metabolic health in a patient.
|
In this co-presentation, we will explore the fascinating link between body composition changes, the use of anti-obesity medications, and the innovative approach of clinician-led obesity care.
|
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|